{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,11,26]],"date-time":"2023-11-26T06:42:47Z","timestamp":1700980967200},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,8,26]],"date-time":"2022-08-26T00:00:00Z","timestamp":1661472000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,8,26]],"date-time":"2022-08-26T00:00:00Z","timestamp":1661472000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Radiat Oncol"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>To investigate the performance of a narrow-scope knowledge-based RapidPlan (RP) model for optimisation of intensity-modulated proton therapy (IMPT) and volumetric modulated arc therapy (VMAT) plans applied to patients with pleural mesothelioma. Second, estimate the potential benefit of IMPT versus VMAT for this class of patients.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>A cohort of 82 patients was retrospectively selected; 60 were used to \"train\" a dose-volume histogram predictive model; the remaining 22 provided independent validation. The performance of the RP models was benchmarked, comparing predicted versus achieved mean and near-to-maximum dose for all organs at risk (OARs) in the training set and by quantitative assessment of some dose-volume metrics in the comparison of the validation RP-based data versus the manually optimised training datasets. Treatment plans were designed for a prescription dose of 44\u00a0Gy in 22 fractions (proton doses account for a fixed relative biological effectiveness RBE\u2009=\u20091.1).<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Training and validation RP-based plans resulted dosimetrically similar for both VMAT and IMPT groups, and the clinical planning aims were met for all structures. The IMPT plans outperformed the VMAT ones for all OARs for the contra-lateral and the mean and low dose regions for the ipsilateral OARs. Concerning the prediction performance of the RP models, the linear regression for the near-to-maximum dose resulted in D<jats:sub>achieved<\/jats:sub>\u2009=\u20091.03D<jats:sub>predicted<\/jats:sub>\u2009+\u20090.58 and D<jats:sub>achieved<\/jats:sub>\u2009=\u20091.02D<jats:sub>predicted<\/jats:sub>\u2009+\u20091.46 for VMAT and IMPT, respectively. For the mean dose it resulted: D<jats:sub>achieved<\/jats:sub>\u2009=\u20090.99D<jats:sub>predicted<\/jats:sub>\u2009+\u20090.34 and D<jats:sub>achieved<\/jats:sub>\u2009=\u20091.05D<jats:sub>predicted<\/jats:sub>\u2009+\u20090.27 respectively. In both cases, the linear correlation between prediction and achievement is granted with an angular coefficient deviating from unity for less than 5%. Concerning the dosimetric comparison between manual plans in the training cohort and RP-based plans in the validation cohort, no clinical differences were observed for the target volumes in both the VMAT and IMPT groups. Similar consistency was observed for the dose-volume metrics analysed for the OAR. This proves the possibility of achieving the same quality of plans with manual procedures (the training set) or with automated RP-based methods (the validation set).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Two models were trained and validated for VMAT and IMPT plans for pleural mesothelioma. The RP model performance resulted satisfactory as measured by the agreement between predicted and achieved (after full optimisation) dose-volume metrics. The IMPT plans outperformed the VMAT plans for all the OARs (with different intensities for contra- or ipsilateral structures). RP-based planning enabled the automation of part of the optimisation and the harmonisation of the dose-volume results between training and validation. The IMPT data showed a systematic significant dosimetric advantage over VMAT. In general, using an RP-based approach can simplify the optimisation workflow in these complex treatment indications without impacting the quality of plans.<\/jats:p><\/jats:sec>","DOI":"10.1186\/s13014-022-02119-x","type":"journal-article","created":{"date-parts":[[2022,8,26]],"date-time":"2022-08-26T13:03:04Z","timestamp":1661518984000},"update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Training and validation of a knowledge-based dose-volume histogram predictive model in the optimisation of intensity-modulated proton and volumetric modulated arc photon plans for pleural mesothelioma patients"],"prefix":"10.1186","volume":"17","author":[{"given":"Davide","family":"Franceschini","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luca","family":"Cozzi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antonella","family":"Fogliata","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Beatrice","family":"Marini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luciana","family":"Di Cristina","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luca","family":"Dominici","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ruggero","family":"Spoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ciro","family":"Franzese","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pierina","family":"Navarria","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tiziana","family":"Comito","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giacomo","family":"Reggiori","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stefano","family":"Tomatis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marta","family":"Scorsetti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,8,26]]},"reference":[{"key":"2119_CR1","first-page":"376","volume":"20","author":"P Hountis","year":"2015","unstructured":"Hountis P, Chounti M, Matthaios D, Romanidis K, Moraitis S. Surgical treatment for malignant pleural mesothelioma: extrapleural pneumonectomy, pleurectomy\/decortication or extended pleurectomy? J Buon. 2015;20:376\u201380.","journal-title":"J Buon"},{"key":"2119_CR2","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1016\/S0022-5223(99)70469-1","volume":"117","author":"DJ Sugarbaker","year":"1999","unstructured":"Sugarbaker DJ, Flores RM, Jaklitsch MT, Richards WG, Strauss GM, Corson JM, et al. Resection margins, extrapleural nodal status, and cell type determine postoperative long-term survival in trimodality therapy of malignant pleural mesothelioma: results in 183 patients. J Thorac Cardiovasc Surg. 1999;117:54\u201365.","journal-title":"J Thorac Cardiovasc Surg"},{"issue":"Suppl 2","key":"2119_CR3","first-page":"S238","volume":"6","author":"I Opitz","year":"2014","unstructured":"Opitz I. Management of malignant pleural mesothelioma: the European experience. J Thorac Dis. 2014;6(Suppl 2):S238\u201352.","journal-title":"J Thorac Dis"},{"key":"2119_CR4","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1016\/j.lungcan.2013.11.026","volume":"83","author":"C Cao","year":"2014","unstructured":"Cao C, Tian D, Park J, Allan J, Pataky KA, Yan TD. A systematic review and meta-analysis of surgical treatments for malignant pleural mesothelioma. Lung Cancer. 2014;83:240\u20135.","journal-title":"Lung Cancer"},{"key":"2119_CR5","doi-asserted-by":"publisher","first-page":"1748","DOI":"10.1016\/j.athoracsur.2014.05.071","volume":"98","author":"O Lauk","year":"2014","unstructured":"Lauk O, Hoda MA, de Perrot M, Friess M, Klikovits T, Klepetko W, et al. Extrapleural pneumonectomy after induction chemotherapy: perioperative outcome in 251 mesothelioma patients from three high-volume institutions. Ann Thorac Surg. 2014;98:1748\u201354.","journal-title":"Ann Thorac Surg"},{"key":"2119_CR6","doi-asserted-by":"publisher","first-page":"1859","DOI":"10.1016\/j.athoracsur.2014.01.050","volume":"97","author":"L Spaggiari","year":"2014","unstructured":"Spaggiari L, Marulli G, Bovolato P, Alloisio M, Pagan V, Oliaro A, et al. Extrapleural pneumonectomy for malignant mesothelioma: an Italian multicenter retrospective study. Ann Thorac Surg. 2014;97:1859\u201365.","journal-title":"Ann Thorac Surg"},{"key":"2119_CR7","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1097\/JTO.0b013e31828353d7","volume":"8","author":"BI Hiddinga","year":"2013","unstructured":"Hiddinga BI, van Meerbeeck JP. Surgery in mesothelioma\u2014where do we go after MARS? J Thorac Oncol. 2013;8:525\u20139.","journal-title":"J Thorac Oncol"},{"key":"2119_CR8","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1586\/ers.10.35","volume":"4","author":"DJ Sugarbaker","year":"2010","unstructured":"Sugarbaker DJ, Wolf AS. Surgery for malignant pleural mesothelioma. Expert Rev Respir Med. 2010;4:363\u201372.","journal-title":"Expert Rev Respir Med"},{"key":"2119_CR9","doi-asserted-by":"crossref","unstructured":"Kindler HL, Ismaila N, Armato SG III et al. Treatment of malignant pleural mesothelioma: American society of clinical oncology clinical practice guideline. J Clin Oncol. 2018:JCO2017766394","DOI":"10.1200\/JOP.17.00012"},{"key":"2119_CR10","doi-asserted-by":"publisher","first-page":"2761","DOI":"10.1200\/JCO.2016.67.2675","volume":"34","author":"A Rimner","year":"2016","unstructured":"Rimner A, Zauderer MG, Gomez DR, et al. Phase II study of hemithoracic intensity-modulated pleural radiation therapy (IMPRINT) as part of lung sparing multimodality therapy in patients with malignant pleural mesothelioma. J Clin Oncol. 2016;34:2761\u20138.","journal-title":"J Clin Oncol"},{"key":"2119_CR11","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1016\/j.cllc.2019.08.008","volume":"21","author":"D Franceschini","year":"2020","unstructured":"Franceschini D, De Rose F, Cozzi S, et al. Volumetric modulated arc therapy after lung sparing surgery for malignant pleural mesothelioma: a single institution experience. Clin Lung Cancer. 2020;21:86\u201393.","journal-title":"Clin Lung Cancer"},{"key":"2119_CR12","doi-asserted-by":"crossref","first-page":"28","DOI":"10.37549\/ARO1107","volume":"5","author":"V Dumane","year":"2016","unstructured":"Dumane V, Yorke ED, Rosenzweig KE. Volumetric-modulated arc therapy for malignant pleural mesothelioma after pleurectomy\/decortication. Appl Radiat Oncol. 2016;5:28\u201337.","journal-title":"Appl Radiat Oncol"},{"key":"2119_CR13","doi-asserted-by":"publisher","first-page":"3842","DOI":"10.1118\/1.4735684","volume":"39","author":"V Dumane","year":"2012","unstructured":"Dumane V, Yorke E, Rimner A, RosenzweigG K. SU-E-T-595: comparison of volumetric modulated arc therapy (VMAT) and static intensity modulated radiotherapy (IMRT) for malignant pleural mesothelioma in patients with intact lungs\/post pleurectomy. Med Phys. 2012;39:3842.","journal-title":"Med Phys"},{"key":"2119_CR14","doi-asserted-by":"publisher","first-page":"e685","DOI":"10.1016\/j.cllc.2018.04.019","volume":"19","author":"S Shaaan","year":"2018","unstructured":"Shaaan S, Verma V, Choi I, Shabason J, Sharma S, Glass E, et al. Utilisation of intensity modulated radiation therapy for malignant pleural mesothelioma in the United States. Clin Lung Cancer. 2018;19:e685\u201392.","journal-title":"Clin Lung Cancer"},{"key":"2119_CR15","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1016\/j.prro.2020.02.007","volume":"10","author":"R Patel","year":"2020","unstructured":"Patel R, Ludmir E, Miccio J, Menon H, Barsky A, Mesko S, et al. Disease-related outcomes and toxicities of intensity modulated radiation therapy after lung-sparing pleurectomy for malignant pleural mesothelioma: a systematic review. Pract Radiat Oncol. 2020;10:423\u201333.","journal-title":"Pract Radiat Oncol"},{"key":"2119_CR16","unstructured":"Zeng J, Badiyan S, Garces Y, Wong T, Zhang X, Simone C et al. Consensus statement on proton therapy in mesothelioma. Pract Radiat Oncol. 2020"},{"key":"2119_CR17","doi-asserted-by":"publisher","first-page":"809","DOI":"10.1016\/j.ijrobp.2014.07.045","volume":"90","author":"JY Chang","year":"2014","unstructured":"Chang JY, Li H, Zhu XR, et al. Clinical implementation of intensity modulated proton therapy for thoracic malignancies. Int J Radiat Oncol Biol Phys. 2014;90:809\u201318.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2119_CR18","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1007\/s00066-011-0038-3","volume":"188","author":"S Lorentini","year":"2021","unstructured":"Lorentini S, Amichetti M, Spiazzi L, et al. Adjuvant intensity-modulated proton therapy in malignant pleural mesothelioma. A comparison with intensity modulated radiotherapy and a spot size variation assessment. Strahlenther Onkol. 2021;188:216\u201325.","journal-title":"Strahlenther Onkol"},{"key":"2119_CR19","first-page":"5678","volume":"16","author":"L Lin","year":"2015","unstructured":"Lin L, Kang M, Huang S, et al. Beam-specific planning target volumes incorporating 4D CT for pencil beam scanning proton therapy of thoracic tumors. J Appl Clin Med Phys. 2015;16:5678.","journal-title":"J Appl Clin Med Phys"},{"key":"2119_CR20","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0145137","volume":"10","author":"A Fogliata","year":"2015","unstructured":"Fogliata A, Nicolini G, Bourgier C, et al. Performance of a knowledge-based model for optimisation of volumetric modulated arc therapy plans for single and bilateral breast irradiation. PLoS ONE. 2015;10: e0145137.","journal-title":"PLoS ONE"},{"key":"2119_CR21","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1186\/s13014-014-0236-0","volume":"9","author":"A Fogliata","year":"2014","unstructured":"Fogliata A, Wang PM, Belosi F, et al. Assessment of a model based optimisation engine for volumetric modulated arc therapy for patients with advanced hepatocellular cancer. Radiat Oncol. 2014;9:236.","journal-title":"Radiat Oncol"},{"key":"2119_CR22","doi-asserted-by":"publisher","first-page":"612","DOI":"10.1016\/j.ijrobp.2014.11.014","volume":"19","author":"J Tol","year":"2015","unstructured":"Tol J, Delaney A, Dahele M, et al. Evaluation of a knowledge-based planning solution for head and neck cancer. Int J Radiat Oncol Biol Phys. 2015;19:612\u201320.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2119_CR23","doi-asserted-by":"publisher","first-page":"e219","DOI":"10.1016\/j.prro.2020.06.003","volume":"11","author":"V Dumane","year":"2021","unstructured":"Dumane V, Tam J, Lo Y, Rosenzweig K. RapidPlan for knowledge-based planning of malignant pleural mesothelioma. Pract Radiat Oncol. 2021;11:e219\u201328.","journal-title":"Pract Radiat Oncol"},{"key":"2119_CR24","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1016\/j.radonc.2017.03.020","volume":"124","author":"A Delaney","year":"2017","unstructured":"Delaney A, Dahele M, Tol J, et al. Using a knowledge-based planning solution to select patients for proton therapy. Radiother Oncol. 2017;124:263\u201370.","journal-title":"Radiother Oncol"},{"key":"2119_CR25","volume":"10","author":"A Delaney","year":"2018","unstructured":"Delaney A, Verbakel W, Lindberg J, et al. Evaluation of an automated proton planning solution. Cureus. 2018;10: e3696.","journal-title":"Cureus"},{"key":"2119_CR26","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1007\/s00066-020-01664-2","volume":"197","author":"L Cozzi","year":"2021","unstructured":"Cozzi L, Vanderstraeten R, Fogliata A, et al. The role of a knowledge based dose\u2013volume histogram predictive model in the optimisation of intensity-modulated proton plans for hepatocellular carcinoma patients. Strahlenther Onkol. 2021;197:332\u201342.","journal-title":"Strahlenther Onkol"},{"key":"2119_CR27","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1080\/0284186X.2020.1845396","volume":"60","author":"E Celik","year":"2021","unstructured":"Celik E, Baues K, Fogliata A, Scorsetti M, Marnitz S, Cozzi L. Knowledge-based intensity-modulated proton planning for gastro-esophageal carcinoma. Acta Oncol. 2021;60:285\u201392.","journal-title":"Acta Oncol"},{"key":"2119_CR28","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1088\/0031-9155\/55\/3\/002","volume":"55","author":"O Vassiliev","year":"2010","unstructured":"Vassiliev O, et al. Validation of a new grid-based Boltzmann equation solver for dose calculation in radiotherapy with photon beams. Phys Med Biol. 2010;55:581\u201398.","journal-title":"Phys Med Biol"},{"key":"2119_CR29","unstructured":"Nocedal J, Wright S. Numerical optimisation. Second Edition. 2006. ISBN-13:978-0387-30303-1."},{"key":"2119_CR30","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1016\/j.ijrobp.2007.03.011","volume":"69","author":"DC Rice","year":"2007","unstructured":"Rice DC, Smythe WR, Liao Z, et al. Dose-dependent pulmonary toxicity after postoperative intensity-modulated radiotherapy for malignant pleural mesothelioma. Int J Radiat Oncol Biol Phys. 2007;69:350\u20137.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2119_CR31","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1016\/j.radonc.2009.03.011","volume":"92","author":"CA Kristensen","year":"2009","unstructured":"Kristensen CA, Nottrup TJ, Berthelsen AK, et al. Pulmonary toxicity following IMRT after extrapleural pneumonectomy for malignant pleural mesothelioma. Radiother Oncol. 2009;92:96\u20139.","journal-title":"Radiother Oncol"},{"key":"2119_CR32","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1111\/php.13065","volume":"95","author":"SR Rice","year":"2019","unstructured":"Rice SR, Li YR, Busch TM, et al. A novel prospective study assessing the combination of photodynamic therapy and proton radiation therapy: Safety and outcomes when treating malignant pleural mesothelioma. Photochem Photobiol. 2019;95:411\u20138.","journal-title":"Photochem Photobiol"},{"key":"2119_CR33","doi-asserted-by":"publisher","first-page":"e345","DOI":"10.1016\/j.prro.2014.11.005","volume":"5","author":"HY Pan","year":"2015","unstructured":"Pan HY, Jiang S, Sutton J, et al. Early experience with intensity modulated proton therapy for lung-intact mesothelioma: a case series. Pract Radiat Oncol. 2015;5:e345\u201353.","journal-title":"Pract Radiat Oncol"},{"issue":"Supplement","key":"2119_CR34","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2018.07.1798","volume":"102","author":"JK Molitoris","year":"2018","unstructured":"Molitoris JK, Glass E, Miller K, et al. Toxicities and clinical outcomes of whole pleural intensity-modulated proton therapy for lung intact malignant pleural mesothelioma. Int J Radiat Oncol Biol Phys. 2018;102(Supplement): e664.","journal-title":"Int J Radiat Oncol Biol Phys"}],"container-title":["Radiation Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13014-022-02119-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13014-022-02119-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13014-022-02119-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,26]],"date-time":"2023-11-26T06:19:08Z","timestamp":1700979548000},"score":1,"resource":{"primary":{"URL":"https:\/\/ro-journal.biomedcentral.com\/articles\/10.1186\/s13014-022-02119-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8,26]]},"references-count":34,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["2119"],"URL":"https:\/\/doi.org\/10.1186\/s13014-022-02119-x","relation":{},"ISSN":["1748-717X"],"issn-type":[{"value":"1748-717X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,8,26]]},"assertion":[{"value":"21 February 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 August 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 August 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Approved by Humanitas Ethical committee as retrospective investigation. All patients at hospital admission.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"L. Cozzi, Clinical Research Scientist at Humanitas Cancer Center, acts as Scientific Advisor to Varian Medical Systems. All other co-authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"150"}}